Pelacarsen cut lipoprotein(a) by 78.4% at 12 months but did not reduce MACE vs placebo in 8322 patients with cardiovascular disease (HR, 1.02).
News|Articles|August 28, 2024
Tried and True: Exploring Metformin’s Potential for Geographic Atrophy
Author(s)Connor Iapoce
A new treatment era was born with first-time geographic atrophy approvals in 2023, but many are still searching for the next addition to the treatment landscape.
Advertisement
Advertisement
Across the continuously evolving world of medicine, true breakthroughs remain rare, but when they happen, they can turn a light at the end of the tunnel into a beacon of hope. For patients battling the relentless advance of
Related to this article
Despite lowering free IL-6 and hsCRP, monthly ziltivekimab did not reduce 3-point MACE vs placebo in 6376 patients with ASCVD and CKD.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Advertisement
Advertisement